Skip to content
Articles

Which GLP-1 Is Best for Weight Loss?

Article illustration: two people reviewing paperwork at a table.

lsmat913 hours ago8 min read

People asking which GLP-1 is best for weight loss usually want a short list with one winner. There is not one. Semaglutide and tirzepatide are different medicines, studied in different people, and a result in a trial is not a promise for the next patient. A clinician has to match the option, if any, to your history, other conditions, and ability to stay with follow-up.

Call (817) 423-5400. Let's begin with a conversation.

Artisan MedSpa, Laser & Wellness in Fort Worth offers medically supervised weight management. A named medicine on a website is a possible topic for that visit, not proof that it is in stock, right for you, or the one you will be offered. This article explains how to compare the class. It is not a prescription and not a substitute for your own clinician.

Why "best" is the wrong first question

A search for which GLP-1 is best for weight loss treats the decision like a product ranking. Medicines in this class act on appetite and blood sugar, but they are not interchangeable. Dose, approved use, other illnesses, and side effects all change the fit.

Trial averages also hide the spread. Some adults lose more than the reported average, and some lose less or stop because they cannot tolerate the medicine. A larger average in one study does not make that medicine the right starting point for every adult in Fort Worth.

The useful question is narrower: which option, if any, is reasonable to discuss for this person, at this time, with a plan for diet, activity, and follow-up. That is a clinical judgment. It is not something a chart on the internet can finish.

How GLP-1 medicines differ

GLP-1 medicines copy a gut hormone that helps regulate appetite and insulin. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on that receptor and also on the GIP receptor, which is why you will see it described as a dual agonist. The extra action is a real difference in design. It is not, by itself, proof that tirzepatide is the better choice for you.

Brand names add another layer of confusion. The same active ingredient can be sold under more than one name, with different approved uses and different doses. Reading "semaglutide" on a label does not tell you which product it is or why it was prescribed.

The FDA label for Ozempic is specific. That semaglutide product is for adults with type 2 diabetes. It can improve blood sugar. It also has separate indications. One reduces cardiovascular risk in certain adults with type 2 diabetes and established cardiovascular disease. Another reduces the risk of kidney disease progression in certain adults with type 2 diabetes and chronic kidney disease. It is not labeled as a general weight-loss medicine.

A diabetes brand and a weight-management brand can share an ingredient. They are still not the same treatment decision. The name on the pen matters as much as the ingredient inside it.

Two products are labeled for long-term weight reduction together with a reduced-calorie diet and more physical activity:

Wegovy (semaglutide)

is a GLP-1 receptor agonist. For weight, the label covers adults with obesity, and adults with overweight plus at least one related condition. A clinician still has to match the person to the use. The label also has a cardiovascular-risk indication for adults with established cardiovascular disease and obesity or overweight.

Zepbound (tirzepatide)

acts on GIP and GLP-1 receptors. For weight, the label covers adults with obesity, or adults with overweight plus at least one related condition. The same label has a separate sleep apnea use in adults with obesity.

Labels change, and a summary is not the full prescribing information. Compounded or differently branded products are a separate question about source and oversight. Ask which exact product is being discussed, and for which labeled reason, before you compare averages.

What studies show, and what they do not

Head-to-head evidence exists, and it has limits. In the SURMOUNT-5 trial, registered as NCT05822830, adults with obesity and without diabetes took tirzepatide or semaglutide for 72 weeks. They used the highest dose they could tolerate.

Average weight change was about 20.2 percent with tirzepatide and about 13.7 percent with semaglutide in the published SURMOUNT-5 results. Waist size also fell more with tirzepatide.

That gap matters inside the study. It is still an average from selected adults who stayed on a protocol, at the highest dose they could tolerate. It does not say what you will lose. It also does not mean you should start at a top dose. Both groups mainly reported stomach and gut effects, often mild or moderate, and often while the dose was going up.

Routine clinic reports have pointed the same way. In a large real-world cohort study, adults with overweight or obesity who started semaglutide or tirzepatide products labeled for type 2 diabetes were compared. Those who started tirzepatide were more likely to reach 5, 10, and 15 percent weight loss than those who started semaglutide. The gap widened over a year of care. Stopping early was common in both groups. Stomach and gut effects were similar.

Read together, the trial and those clinic reports support one careful statement. In the groups studied, tirzepatide produced more average weight loss than semaglutide. They do not mean tirzepatide is best for everyone. They also do not predict your result. Tolerance, other diseases, and whether you can stay on the medicine all change the outcome.

Which GLP-1 is best for weight loss in your situation

When someone asks which GLP-1 is best for weight loss, a careful answer starts with the person, not the leaderboard. The factors below are discussion points. They are not a scoring system you can finish at home.

Factor a clinician may weigh

Why it can change the fit

What to bring up

The reason for treatment.

Diabetes, heart disease, sleep apnea, and weight goals are not the same indication.

Bring your diagnoses and what you most need help with.

Current medicines.

Labels say not to combine these products with another GLP-1 medicine.

List every prescription, including any GLP-1 you already use.

Thyroid history.

Wegovy and Zepbound labels warn about a thyroid tumor risk seen in rodents.

Share any personal or family history of medullary thyroid cancer or MEN 2.

Stomach and pancreas history.

Nausea and related effects are common, and some histories need extra care.

Mention pancreatitis, severe reflux, gallbladder disease, or past intolerance.

Pregnancy plans.

Tell the clinician if you are pregnant, planning pregnancy, or breastfeeding. Weight-loss treatment is not recommended during pregnancy.

Say whether you are pregnant, trying, or breastfeeding.

Ability to follow up.

Doses usually rise over time, and stopping early is common in clinic data.

Raise travel, cost questions, and who will monitor you.

Artisan's wellness page describes an evaluation that can include an exam, blood work, and an EKG, plus body-composition checks and later visits in person or by telemedicine when appropriate. Which pieces apply is the clinician's call. The visit is where this table becomes personal. It is not a promise that every test, or any specific medicine, is part of your plan.

If you want the shape of that first visit, the GLP-1 consultation overview covers what the conversation can and cannot decide. This article stays on the comparison.

How a Fort Worth clinician narrows the options

A comparison visit is a sequence, not a menu you point at. The order can vary, and a step can end the conversation if the medicine is a poor fit.

Confirm the goal and the medical reason. Weight, blood sugar, heart risk, and sleep apnea can point to different labeled uses.

Review history, medicines, and exclusions. A personal or family history of medullary thyroid carcinoma, or MEN 2, is a label-level reason not to use Wegovy or Zepbound.

Decide whether more information is needed before any medicine is discussed in detail.

If a GLP-1 option is still reasonable, name the exact product, the indication being considered, and what the dose path usually looks like.

Set follow-up before you start. Ask what should prompt a call, and what happens if you cannot tolerate a dose.

Nothing in that sequence requires the clinician to prescribe. A reasonable outcome is a different plan, more testing, or a referral back to the physician who manages your diabetes or heart disease. Interest in a brand name is not eligibility.

For how an injectable option is assessed locally, without turning this into a visit guide, see weight loss injections in Fort Worth. The broader program, including counseling and repeat visits, is described under medically supervised weight management.

Side effects change the ranking

A medicine you cannot continue is not the best one for you, even if its trial average is higher. Nausea, vomiting, diarrhea, and constipation are the effects people most often report with both semaglutide and tirzepatide, especially while the dose is going up. Most are described as mild or moderate in the studies above. Some are not, and some people stop.

The Wegovy and Zepbound labels also carry a boxed warning. In rodent studies, these drugs caused thyroid C-cell tumors. It is unknown whether the same tumors occur in people. Both products are ruled out if you or a family member has had medullary thyroid cancer. They are also ruled out if you have MEN 2, a rare inherited syndrome.

That warning is a reason to tell your clinician about thyroid history. It is not a reason to order your own screening tests from a list you found online.

Other label warnings include pancreatitis, gallbladder problems, low blood sugar when certain diabetes medicines are also used, kidney problems if you become dehydrated, and possible mood changes. The full list is on the prescribing information, and your own risk depends on the rest of your chart. Do not stop another prescribed medicine to "make room" for a GLP-1 product unless the prescribing clinician tells you to.

A full side-effect review is its own conversation. Bring symptoms you have had on any prior weight-loss or diabetes medicine so the comparison is about your tolerance, not a stranger's.

What Artisan can and cannot decide for you

Artisan MedSpa, Laser & Wellness describes physician-led wellness care at 6015 Harris Parkway, Suite 110, Fort Worth. Weight management is one part of that work. The public wellness page has listed semaglutide, using Ozempic as an example, and tirzepatide, using Mounjaro as an example, among possible program components.

Read that list as a list of topics a clinician might discuss, not as a shelf inventory and not as a recommendation. Ozempic and Mounjaro are diabetes brands. Their labels are not the same as the Wegovy and Zepbound weight-management labels, even when the active ingredient overlaps. Which product, if any, is appropriate is decided one patient at a time.

The practice does not publish a price for these medicines here, and this article will not invent one. Insurance, supply, and the exact product all change cost. Ask during a consultation rather than comparing advertised specials.

If you want help preparing questions, the guide on questions to ask about weight loss medication is the better place for that list. Bring your medicine list, relevant records, and a clear statement of what you hope to change.

If you want a clinician to sort these options for your own history, call (817) 423-5400 or use the contact form.

Frequently asked questions

Is tirzepatide always better than semaglutide for weight loss?

No. In SURMOUNT-5, and in a large clinic study, average weight loss was greater with tirzepatide. Those are group results. Your other conditions, the labeled reason for treatment, and whether you can tolerate the dose can point the other way.

Is Ozempic the best GLP-1 for weight loss?

Ozempic is semaglutide labeled for type 2 diabetes and related risks in people who have diabetes. It is not the product labeled for general weight management. Wegovy is the semaglutide product with that weight indication. A clinician has to choose the product for the indication, not the nickname.

Can I pick a GLP-1 from a comparison chart?

A chart can show differences. It cannot apply them to your thyroid history, pregnancy plans, other medicines, or follow-up. Use it to prepare questions, then let a clinician decide whether any GLP-1 medicine belongs in the plan.

How long would I need to stay on treatment?

Labels for Wegovy and Zepbound discuss long-term weight reduction, not a short cleanse. Many people in routine-care data stop within a year. Duration, dose, and what happens after a stop are individual decisions that belong in follow-up, not in a headline.

Does a consultation mean I will get the medicine with the biggest average weight loss?

No. A consultation is an evaluation. The outcome can be a specific product, a different approach, more testing, or no medicine. Average weight change in a study is one input, not the assignment.